scholarly journals Development of Cell Cycle Inhibitors for Cancer Therapy

2009 ◽  
Vol 16 (2) ◽  
Author(s):  
Gary K. Schwartz ◽  
Mark Dickson
Keyword(s):  
Cell Cycle ◽  
Cancer Therapy ◽  
Cell Cycle Inhibitors

Cell Cycle Inhibitors in Cancer Therapy

2002 ◽  
Author(s):  
Antonio Giordano ◽  
Kenneth J. Soprano
Keyword(s):  
Cell Cycle ◽  
Cancer Therapy ◽  
Cell Cycle Inhibitors

scholarly journals Development of Chemotherapy with Cell-Cycle Inhibitors for Adult and Pediatric Cancer Therapy

2018 ◽  
Vol 78 (2) ◽  
pp. 320-325 ◽  
Author(s):  
Christopher C. Mills ◽  
EA. Kolb ◽  
Valerie B. Sampson
Keyword(s):  
Cell Cycle ◽  
Cancer Therapy ◽  
Pediatric Cancer ◽  
Cell Cycle Inhibitors

Emerging cell-cycle inhibitors for pancreatic cancer therapy

2012 ◽  
Vol 17 (4) ◽  
pp. 571-582 ◽  
Author(s):  
Soley Bayraktar ◽  
Caio M Rocha Lima
Keyword(s):  
Cell Cycle ◽  
Pancreatic Cancer ◽  
Cancer Therapy ◽  
Cell Cycle Inhibitors ◽  
Pancreatic Cancer Therapy

scholarly journals Targeting Non-Oncogene Addiction for Cancer Therapy

Biomolecules ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. 129
Author(s):  
Hae Ryung Chang ◽  
Eunyoung Jung ◽  
Soobin Cho ◽  
Young-Jun Jeon ◽  
Yonghwan Kim
Keyword(s):  
Cell Cycle ◽  
Dna Replication ◽  
Cancer Therapy ◽  
Cell Cycle Regulation ◽  
Synthetic Lethality ◽  
Current Knowledge ◽  
Cancer Therapies ◽  
Oncogene Addiction ◽  
Clinical Biomarkers ◽  
Cycle Regulation

While Next-Generation Sequencing (NGS) and technological advances have been useful in identifying genetic profiles of tumorigenesis, novel target proteins and various clinical biomarkers, cancer continues to be a major global health threat. DNA replication, DNA damage response (DDR) and repair, and cell cycle regulation continue to be essential systems in targeted cancer therapies. Although many genes involved in DDR are known to be tumor suppressor genes, cancer cells are often dependent and addicted to these genes, making them excellent therapeutic targets. In this review, genes implicated in DNA replication, DDR, DNA repair, cell cycle regulation are discussed with reference to peptide or small molecule inhibitors which may prove therapeutic in cancer patients. Additionally, the potential of utilizing novel synthetic lethal genes in these pathways is examined, providing possible new targets for future therapeutics. Specifically, we evaluate the potential of TONSL as a novel gene for targeted therapy. Although it is a scaffold protein with no known enzymatic activity, the strategy used for developing PCNA inhibitors can also be utilized to target TONSL. This review summarizes current knowledge on non-oncogene addiction, and the utilization of synthetic lethality for developing novel inhibitors targeting non-oncogenic addiction for cancer therapy.

A novel CyclinE/CyclinA-CDK Inhibitor targets p27Kip1 degradation, cell cycle progression and cell survival: Implications in cancer therapy

2013 ◽  
Vol 333 (1) ◽  
pp. 103-112 ◽  
Author(s):  
Lu Dai ◽  
Yuqing Liu ◽  
Junyang Liu ◽  
Xiaoming Wen ◽  
ZhengShuang Xu ◽  
...  
Keyword(s):  
Cell Cycle ◽  
Cancer Therapy ◽  
Cell Survival ◽  
Cell Cycle Progression ◽  
Cdk Inhibitor ◽  
Cycle Progression

Evaluation of NovelN-(piperidine-4-yl)benzamide Derivatives as Potential Cell Cycle Inhibitors in HepG2 Cells

2014 ◽  
Vol 86 (2) ◽  
pp. 223-231 ◽  
Author(s):  
Jin Hou ◽  
Wei Zhao ◽  
Zhi-Ning Huang ◽  
Shao-Mei Yang ◽  
Li-Juan Wang ◽  
...  
Keyword(s):  
Cell Cycle ◽  
Hepg2 Cells ◽  
Cell Cycle Inhibitors ◽  
Benzamide Derivatives
Sign in / Sign up

Export Citation Format

Share Document